Methocarbamol is NOT Safe in Children Under 12 Years Old
Methocarbamol should not be used in children under 16 years of age, as safety and effectiveness have not been established in this population. 1
FDA-Approved Labeling Position
The FDA drug label for methocarbamol explicitly states: "Safety and effectiveness of methocarbamol in pediatric patients below the age of 16 have not been established." 1 This is the highest-quality evidence available and represents the official regulatory position based on lack of adequate clinical trial data in children.
Key Safety Concerns
Lack of Pediatric Data:
- No controlled studies have evaluated methocarbamol's safety profile in children under 16 years
- Dosing parameters, pharmacokinetics, and adverse effect profiles have not been characterized in pediatric populations
- The drug's CNS-depressant effects may pose unpredictable risks in developing nervous systems 1
Pregnancy and Developmental Concerns:
- Methocarbamol is Pregnancy Category C with reports of fetal and congenital abnormalities following in utero exposure 1
- The drug should not be used in women who may become pregnant, particularly during early pregnancy, unless potential benefits clearly outweigh risks 1
- This developmental concern extends logically to pediatric use where organ systems are still maturing
Anticholinergic Adverse Effects:
- Recent evidence demonstrates that methocarbamol causes anticholinergic adverse drug events in 10.8% of adult ICU patients 2
- Children may be more susceptible to anticholinergic effects including urinary retention, confusion, and altered mental status
- These effects required intervention in 79% of cases in critically ill adults 2
Clinical Implications
Alternative Approaches for Pediatric Muscle Spasm/Pain:
- Use age-appropriate analgesics with established pediatric safety profiles
- Consider non-pharmacologic interventions (physical therapy, heat/cold application)
- If muscle relaxation is essential, consult pediatric specialists for evidence-based alternatives with pediatric dosing data
Common Pitfall to Avoid: Do not extrapolate adult dosing to children based on weight alone. The absence of pediatric safety data is not the same as evidence of safety—it represents a knowledge gap that places children at unknown risk.